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To elucidate the association between killer cell immunoglobulin-like receptors (KIRs) and psoriasis vulgaris (PV),
we typed 14 KIR genes in 96 Japanese cases and 50 healthy controls using PCR with sequence-speciﬁc primers
(PCR-SSP). Here we report an interesting association between certain KIRs and Japanese cases with PV. The
frequencies of KIR2DS1 and KIR2DL5 were signiﬁcantly increased in PV cases compared with controls (KIR2DS1,
43 of 96 (45%) in cases vs 14 of 50 (28%) in controls; KIR2DL5, 46 of 96 (48%) in cases vs 15 of 50 (30%) in controls,
po0.05 for both), and the frequency of carriage of at least one presumed ‘‘B’’ haplotype, inferred from patterns
including KIR2DL2, KIR2DL5, and/or various combinations of activating KIRs, was also statistically increased in the
PV cases (53 of 96 (55%) in cases vs 18 of 50 (36%) in controls, po0.04). The increase in KIR2DS1 has also been
observed in psoriatic arthritis, another HLA-Cw6-associated disease (Martin et al, 2002). Accordingly, KIR2DS1may
be a common denominator of both diseases.
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Psoriasis is a chronic inflammatory skin disease with a
pathogenesis that has remained obscure. It is generally
accepted that the disease is strongly associated with HLA-
Cw6 and extensive studies have focused on T lymphocytes
as the central pathogenic cells. Recently, T cells bearing
natural killer receptors (NKRs) were precisely and strongly
targeted as new putative pathogenic immunocytes in
psoriasis by Nickoloff (1999). T cells bearing NKR (NK-T
cells) were shown to induce psoriatic plaques in a severe
combined immunodeficient (SCID) mouse model (Nickoloff
et al, 1999, 2000), to produce IFN-g as the trigger for
psoriasis (Fierlbeck et al, 1990), and also were found in
biopsies of chronic plaques from psoriatics (Nickoloff and
Wrone-Smith, 1999).
Among NKR, including the C-type lectin family and
immunoglobulin superfamily, killer cell immunoglobulin-like
receptor (KIR) is the major molecule recognizing HLA-C
(Long, 1999; Borrego et al, 2002) and, therefore, might be
closely related to psoriasis. KIRs are encoded by approxi-
mately 14 genes in a region called the human leukocyte
receptor cluster on chromosome 19q13.4 (Wende et al,
1999; Martin et al, 2000; Wilson et al, 2000) and the KIR-
gene content shows individual variation (Uhrberg et al,
1997). Structurally, KIRs are divided into two types,
although the precise function and the ligands of some
KIRs, including KIR2DL4, remain controversial (Farag et al,
2002). One type consists of activating KIRs (KIR2DS and
KIR3DS), which have a short (S) cytoplasmic tail and
activate NK and NK-T cells by association with DAP12 that
carries a cytoplasmic immunoreceptor tyrosine kinase
activation motif (Long, 1999; Borrego et al, 2002). The other
type consists of the inhibitory KIR (KIR2DL and KIR3DL),
which have one or two immunoreceptor tyrosine-based
inhibition motifs in their long (L) cytoplasmic tail. In these
receptors, KIR2DL1 and KIR2DS1 can recognize Group 2
HLA-C, which consists of HLA-Cw2, -Cw4, -Cw5, -Cw6,
and related alleles (Long, 1999; Nickoloff, 1999; Borrego
et al, 2002). Furthermore, KIR2DS1 was reported to be
correlated with an HLA-Cw6-associated disease, psoriatic
arthritis (Martin et al, 2002). In this study, we typed 14 KIR
genes in 96 Japanese patients and 50 healthy controls
using PCR with sequence-specific primers (PCR-SSP) to
elucidate the association between KIR and another HLA-
Cw6-associated disease, psoriasis vulgaris (PV).
Results
In this study, we typed 14 KIR genes in 96 Japanese cases
and 50 healthy controls. The frequency of each KIR
is shown in Table I. Generally, three framework genes
(KIR2DL4, KIR3DL2, and KIR3DL3) were detected in almost
all the PV cases and controls. But in PV, KIR2DL1
Abbreviations: KIR, killer cell immunoglobulin-like receptor; NKR,
NK receptor; PCR-SSP, PCR with sequence-specific primer; PV,
psoriasis vulgaris
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corresponding to group 2 HLA-C and KIR3DL1 correspond-
ing to HLA-Bw4 were absent in some cases (an approxi-
mately 7% loss for KIR2DL1 and 14% loss for KIR3DL1,
which were not significant at the 5% level), although they
were almost all detected in controls. In the respective
comparison, KIR2DS1 (43 of 96 (45%) in cases vs 14 of 50
(28%) in controls) and KIR2DL5 (46 of 96 (48%) in cases vs
15 of 50 (30%) in controls) were significantly increased in PV
cases at the 5% level (w2-test), although the logistic analysis
that was attempted to overcome the multiple testing
problem was not able to distinguish them statistically,
possibly because of the small sample size.
Furthermore, some representative genotypes and their
assumed haplotype combinations observed in our experi-
ments are shown in Table II. The most frequent genotype in
both cases and controls was the homozygote of the ‘‘A’’
haplotype (haplotype combination AA) as shown in the right
half of this table. This haplotype combination AA is the
Japanese predominant genotype as reported by Yawata
et al (2002). Furthermore, the comparison of donors without
the ‘‘B’’ haplotype (haplotype combination AA) and donors
with at least one ‘‘B’’ haplotype (haplotype combination
AB/BB) was focused, because significantly increased
KIR2DL5 is a marker of the ‘‘B’’ haplotype. As shown in
the right half of Table II, donors with at least one ‘‘B’’
haplotype (haplotype combination AB/BB) significantly
increased in PV cases (53 of 96 (55%) in cases vs 18 of
50 (36%) in controls, p¼0.036, two-sided Fisher’s exact
test) This indicated an increase in the ‘‘B’’ haplotype and a
simultaneous decrease in the homozygotic ‘‘A’’ hapolotype
in PV cases.
Discussion
The results of our study showed a significant increase in
donors with KIR2DS1 and/or KIR2DL5 and donors with at
least one of the ‘‘B’’ haplotypes of PV. These phenomena
would be explained by the occurrence of a substantial
increase in one of the ‘‘B’’ haplotype groups in PV.
According to the KIR haplotype model based on family
studies and genomic sequencing by Hsu et al (2002), all the
haplotypes with KIR2DS1 simultaneously have KIR2DL5
upstream, but KIR2DL5 does not always coexist with
KIR2DS1. This haplotype structure of KIR indicates that
an increase in KIR2DS1 leads to a secondary increase in
KIR2DL5 in donors. Indeed, in our results, the frequencies
of KIR2DS1 and KIR2DL5 were nearly identical in the
respective groups (45% for 2DS1 and 48% for 2DL5 in
cases; 28% for 2DS1 and 30% for 2DL5 in controls, Table I),
and all the genotypes with KIR2DS1 also possessed
KIR2DL5, as partly shown in Table II. Examination of these
frequencies relative to the frequencies of the haplotype
combination AA/AB in Table II revealed that haplotypes with
both KIR2DS1 and KIR2DL5 account for a large proportion
of the ‘‘B’’ haplotypes. This finding suggests that the
increase in ‘‘B’’ haplotypes in PV cases was derived largely
from an increase in some haplotype group with KIR2DS1.
Interestingly, KIR2DS1 also showed the most significant
increase in psoriatic arthritis, as described by Martin et al
(2002). Our data suggest some critical significance of
KIR2DS1 and/or haplotypes with KIR2DS1 in the HLA-
Cw6-related disease, although PV and psoriatic arthritis
may not be identical.
The relationship between the increase in ‘‘B’’ haplotypes
and their activating ligands requires further study. KIR2DS1
is certainly an attractive candidate for exerting a direct
effect on pathogenesis, as it is known to interact with HLA-
Cw6 and has been independently implicated in psoriatic
arthritis (Martin et al, 2002). But if this were the predominant
disease-causing effect, one might expect to see increases
in other HLA-C alleles that interact with KIR2DS1 (i.e., Cw2,
Cw4, and Cw5), and this has not proved to be the case.
Additional studies will be required to determine whether
Table I. Frequency of respective KIR in 96 PV cases and 50 healthy controls
KIR gene:
2DL 3DL 2DS 3DS
1 2 3 4 5 1 2 3 1 2 3 4 5 1
Ligand HLA: HLA-C HLA-C HLA-C HLA-G HLA-B HLA-A HLA-C HLA-C
Grp. 2 Grp. 1 Grp. 1 Bw4 A3, A11 Grp. 2 Grp. 1
PV (N¼96)
þ 89 25 95 95 46 83 95 96 43 19 14 80 34 37
 7 71 1 1 50 13 1 0 53 77 82 16 62 59
% (þ ) 93 26 99 99 48 86 99 100 45 20 15 83 35 39
Control (N¼50)
þ 50 8 49 50 15 48 50 50 14 8 4 47 10 12
 0 42 1 0 35 2 0 0 36 42 46 3 40 38
% (þ ) 100 16 98 100 30 96 100 100 28 16 8 94 20 24
Group (Grp.) 1: HLA-C: HLA-C Ser77Asn80 (Cw1, Cw3, Cw7, Cw8, and related alleles). Grp. 2: HLA-C: HLA-C Asn77Lys80 (Cw2, Cw4, Cw5, Cw6,
and related alleles). Asterisks indicate significant differences to control (w2-test, po0.05). PV, psoriasis vulgaris; KIR, killer cell immunoglobulin-like
receptors.
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KIR2DS1 is directly responsible for the effects we have
observed, as opposed to one or more other features of KIR
‘‘B’’ haplotypes. Nevertheless, the possibility of some
important functional links between activating KIRs, HLA-
Cw6, and PV has emerged via the activating molecule of
KIR2DS1; however, activating KIRs have not been identified
as susceptible genes by genome-wide scans so far. This
might be attributable to the relatively high frequency of
KIR2DS1 (approximately 30%), as power to detect linkage
declines as disease allele frequency increases. Also, linkage
may be obscured because of requirements for other,
unlinked genes and/or environmental factors that reduce
the penetrance of the disease allele. Association strategies
have been shown to be much more powerful than linkage
studies in this setting (Risch and Merikangas, 1996).
Besides direct interaction with the HLA molecule, the
structurally distinctive character of ‘‘B’’ haplotypes is the
multiplicity of activating KIRs with short cytoplasmic tails,
and this character was reflected in the multiplicity of
activating KIRs in donors with haplotypes AB and BB, as
shown in Table II. Activating KIRs recognize not only the
paired ligand HLA class I but also foreign or microbial
antigens (Hsu et al, 2002; Martin et al, 2002). This
multiplicity of activating KIRs, if expressed functionally,
might increase the chance of accidental activation of imm-
unocytes over the threshold. Moreover, this inaccurate acti-
vation would occur especially in patients who do not possess
the proper combination of inhibitory KIRs and the ligand
HLA. More specifically, if there are no paired HLA, inhibitory
KIRs, even if they exist, cannot inhibit the activation of
immunocytes, and vice versa. This possibility had already
been suggested by Martin et al (2002); however, the size of
our HLA-typed samples was not large, and whether or not
mismatching between HLA class I, activating KIRs, and
inhibitory KIRs is predisposed to PV remains obscure.
In summary, genotypes with ‘‘B’’ haplotypes, especially
those containing KIR2DS1 and KIR2DL5, were found to be
increased in Japanese PV cases, and this phenomenon
seemed to be caused by an increase in some haplotype
group possessing KIR2DS1. This association of KIR2DS1
with PV is strongly concurrent with the previous implication
of KIR2DS1 in psoriatic arthritis, another HLA-Cw6-asso-
ciated disease (Martin et al, 2002). Thus, KIR2DS1 may be
a common denominator in both HLA-Cw6-associated
diseases. KIR genotyping would provide a new interesting
therapeutic strategy for considering the molecular basis
of PV.
Materials and Methods
DNA isolation Samples from 96 unrelated Japanese patients with
PV were collected after receiving their informed consent and
authorization from the Ethical Review Committee of Gene Analysis
Research, Yamaguchi University, School of Medicine, and Uni-
versity Hospital, according to the Declaration of Helsinki principles.
Fifty control samples were also obtained from unrelated healthy
controls. Each genomic DNA was extracted using the QIAmp DNA
Blood Maxi Kit (QIAGEN K.K., Tokyo, Japan) and stored at 201C
before use.
PCR DNA samples were genotyped using PCR-SSP for the
following KIR: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2,
3DL3, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1. The PCR
primers and conditions used were in accordance with the method
described in a previous report (Go´mez-Lozano and Vilches, 2002).
The human growth hormone (GH1) served as a positive marker of
PCR. All primers were synthesized and validated by Hokkaido
System Science Co., Ltd (Hokkaido, Japan). PCR was conducted
by the Gene Amp PCR system 9600-R (Perkin–Elmer, Norwalk,
USA.). Briefly, approximately 100 ng of genomic DNA was
amplified in 20 mL TaKaRa EX Taq buffer with 2 mM Mg2þ , 200
mM dNTP, and 0.5 U TaKaRa EX Taq polymerase (Takara Bio Inc.,
Shiga, Japan). After the initial denaturation for 2 min at 951C,
samples were amplified in 10 cycles of 20 s at 941C, 10 s at 651C,
and 1 min 30 s at 721C; and 20 cycles of 20 s at 941C, 20 s at 611C,
and 1 min 30 s at 721C. Ambiguous typing results were checked by
Table II. Representative KIR genotypes in 96 PV cases and 50 healthy controls and frequency of their halotype combinations
Assumed
haplotypes
KIR with long cytoplasmic tail KIR with short cytoplasmic tail
Assumed
haplotypes
Frequency of donor (%)
2DL 3DL 2DS 3DS
PV Control1 2 3 4 5 1 2 3 1 2 3 4 5 1
AA AA 43/96 (45) 32/50 (64)
AB 44/96 (46) 17/50 (34)
AB BB 9/96 (9) 1/50 (2)
AB p¼ 0.060
AB
AA 43/96 (45) 32/50 (64)
BB AB/BB 53/96 (55) 18/50 (36)
BB p¼ 0.036
AA: a homozygous ‘‘A’’ haplotype, the predominant KIR genotype in healthy Japanese. BB: combination of two ‘‘B’’ haplotypes without 3DL1 and
2DS4, makers of ‘‘A’’ haplotype. AB: combinations other than haplotypes combination AA and BB. AB/BB: haplotype combination AB or BB,
combination with at least one ‘‘B’’ haplotype. Value of p: frequency distribution of donor in PV vs control was tested for Fisher’s exact test.
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sequencing or other PCR systems using several distinct primer
sets (Martin et al, 2002).
KIR genotyping PCR products were electrophoresed on 1.2%
agarose gels with ethidium bromide, and each sample was
genotyped. The frequency (%) of each KIR was calculated as the
percentage of positive numbers among all specimens. After the
genotyping of KIR, the homozygous ‘‘A’’ haplotype was determined
by the presence of only a set of KIRs: 2DL1, 2DL3, 2DL4, 3DL1,
3DL2, 3DL3, and 2DS4, and the heterogenous ‘‘B’’ haplotypes
were inferred from patterns including KIR2DL2, KIR2DL5, and/or
various combinations of activating KIR (Go´mez-Lozano and
Vilches, 2002; Yawata et al, 2002). Furthermore, genotypes
observed in our experiments were defined as haplotype combina-
tions, AA, AB, and BB. Haplotype combination AA is a homo-
zygous ‘‘A’’ haplotype, and haplotype combination BB has
combinations of two ‘‘B’’ haplotypes without 3DL1 and 2DS4,
which are the markers of the ‘‘A’’ haplotype (Yawata et al, 2002).
Haplotype combination AB consists of various heterogenous
combinations of the ‘‘A’’ and ‘‘B’’ haplotypes. In our PCR system,
KIR1D, the common variant of KIR2DS4 in the Caucasian
population (Hsu et al, 2002), was not distinguished from KIR2DS4.
The ‘‘A’’ haplotype in our data contained both haplotype A-1D and
haplotype A-2DS4 described by Hsu et al (2002).
Statistical analysis Frequency differences were tested for sig-
nificance by the two-sided Fisher’s exact test or the w2-test.
Multifactorial analysis was also attempted by logistic analysis (the
SAS system).
This work was supported by grants (Nos. 12204079, 13204063, and
15591178) from the Ministry of Education, Culture, Sports, Science and
Technology of Japan.
DOI: 10.1111/j.0022-202X.2004.22517.x
Manuscript received June 9, 2003; revised December 16, 2003;
accepted for publication December 22, 2003
Address correspondence to: Masahiko Muto, Department of Derma-
tology and Biomolecular Recognition, School of Medicine, Yamaguchi
University, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
Email: mmuto@yamaguchi.u.ac.jp
References
Borrego F, Kabat J, Kim DK, et al: Structure and function of major histocompat-
ibility complex (MHC) class I specific receptors expressed on human
natural killer (NK) cells. Mol Immunol 38:637–660, 2002
Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell
receptors: New biology and insights into the graft-versus-leukemia effect.
Blood 15:1935–1947, 2002
Fierlbeck G, Rassner G, Muller C: Psoriasis induced at the injection site of
recombinant interferon gamma. Results of immunohistologic investiga-
tions. Arch Dermatol 126:351–355, 1990
Go´mez-Lozano N, Vilches C: Genotyping of human killer-cell immunoglobulin-like
receptor genes by polymerase chain reaction with sequence-specific
primers: An update. Tissue Antigens 59:84–93, 2002
Hsu KC, Chida S, Geraghty DE, Dupont B: The killer cell immunoglobulin-like
receptor (KIR) genomic region: Gene-order, haplotypes and allelic
polymorphism. Immunol Rev 190:40–52, 2002
Long EO: Regulation of immune responses through inhibitory receptors. Annu
Rev Immunol 17:875–904, 1999
Martin AM, Freitas EM, Witt CS, Christiansen FT: The genomic organization and
evolution of the natural killer immunoglobulin-like receptor (KIR) gene
cluster. Immunogenetics 51:268–280, 2000
Martin MP, Nelson G, Lee JH, et al: Cutting edge: Susceptibility to psoriatic
arthritis: Influence of activating killer Ig-like receptor genes in the absence
of specific HLA-C alleles. J Immunol 169:2818–2822, 2002
Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol
135:1104–1110, 1999
Nickoloff BJ, Bonish B, Huang BB, Porcelli SA: Characterization of a T cell line
bearing natural killer receptors and capable of creating psoriasis in a
SCID mouse model system. J Dermatol Sci 24:212–225, 2000
Nickoloff BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4þ T cells
induces psoriasis. Am J Pathol 155:145–158, 1999
Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA: Response of murine and
normal human skin to injection of allogeneic blood-derived psoriatic
immunocytes: Detection of T cells expressing receptors typically present
on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol
135:546–552, 1999
Risch N, Merikangas K: The future of genetic studies of complex human
diseases. Science 273:1516–1517, 1996
Uhrberg M, Valiante NM, Shum BP, et al: Human diversity in killer cell inhibitory
receptor genes. Immunity 7:753–763, 1997
Wende H, Colonna M, Ziegler A, Volz A: Organization of the leukocyte receptor
cluster (LRC) on human chromosome 19q13.4. Mamm Genome 10:154–
160, 1999
Wilson MJ, Torkar M, Haude A, et al: Plasticity in the organization and sequences of
human KIR/ILT gene families. Proc Natl Acad Sci USA 97:4778–4783, 2000
Yawata M, Yawata N, McQueen KL, et al: Predominance of group A KIR
haplotypes in Japanese associated with diverse NK cell repertoires of KIR
expression. Immunogenetics 54:543–550, 2002
1136 SUZUKI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
